Efficacy and Safety of Novosis Putty for Degenerative Lumbar Disease

Inclusion Criteria: * Adult aged ≥ 22 to ≤ 80 years * Subjects whose skeletal maturation are confirmed by showing the result of Risser stage 5 in Risser classification, the Plain Radiography * Subjects diagnosed with disc degeneration in the single level (L2-S1) lumbar spine along with spondylolisthesis of Meyerding grade 1 (degree of translocation: 0- \<25%) or 2 (degree of translocation: 25- \<50%) based on the results of radiological examination (CT, MRI, X-ray). * Subjects with an ODI (Oswestry Disability Index) score of ≥ 35/100 at screening * Subjects who were treated with non surgical treatment/therapy for at least 3 months, but were judged to have failed treatment by the investigator * Subjects who are willing to participate in the study, comply with treatment and procedures, and visit the hospital for all observational evaluations * Subjects who voluntarily signed the informed consent form after hearing the explanation on objectives and methods of this study Exclusion Criteria: * Subjects who have a history of medical device application (spinal instrumentation, for example, anterior disc replacement, interspinous device) to the target site or interbody fusion * Subjects who are considered that the symptoms occurring in the lumbar region are not occurred by disc degeneration * Subjects with active malignancy * Subjects with a documented history of drug abuse (e.g., psychotropic drugs including narcotic analgesics and drugs with high dependence such as alcohol) within the last 6 months * Subjects with a history of endocrine or metabolic disorders known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehler Danlos disease, or osteogenesis imperfecta) * Subjects with BMI ≥ 35 * Subjects with spondylolis thesis/retrolisthesis with ≥ Grade 3 in the target level * Subjects with a local acute infection at the current surgical site or active systemic infection (e.g., viral infections such as AIDS, HIV or hepatitis) * Subjects with a history of metabolic or endocrine diseases known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers Danlos disease, osteogenesis imperfecta, fibrous dysplasia, etc.) * Subjects with osteoporosis with a mean lumbar spine T-score of ≤ 2.5 on the DEXA bone density test and with a history of osteoporotic fractures (wrist fractures, femur fractures, lumbar spine fractures, etc.) * Subjects who need to administer drugs that inhibit bone metabolism within 2 weeks after surgery, or Subjects who need to receive post operative drugs that are expected to interfere with bone fusion, such as steroids * Subjects who smoke ≥ 20 cigarettes a day * Subjects with autoimmune disease * Subjects who were exposed to rhBMP 2 in the past * Subjects who require to get fusion of two or more vertebral levels * Subjects who have a pseudoarthrosis after previous fusion * Subjects who had a history of at least one non fusion spinal surgery on the level to be operated * Subjects who are considered to have a disease that hinders the accurate evaluation (e.g., neuromuscular disease, serious psychiatric disease) at the discretion of the investigator * Subjects who are pregnant at screening or who are planning to become pregnant during the study participation period * Subjects who are currently lactating or who are planning to lactate during the study * Subjects who participated in studies for other drugs, biologics, or medical devices within 6 months from the date of surgery * Subjects who are in a difficult situation to comply with study related matters